<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0120-8748</journal-id>
<journal-title><![CDATA[Acta Neurológica Colombiana]]></journal-title>
<abbrev-journal-title><![CDATA[Acta Neurol Colomb.]]></abbrev-journal-title>
<issn>0120-8748</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Neurología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0120-87482025000100004</article-id>
<article-id pub-id-type="doi">10.22379/anc.v41i1.1847</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Inmunosupresores en pacientes con manifestaciones neurológicas de patologías reumatológicas: revisión panorámica]]></article-title>
<article-title xml:lang="en"><![CDATA[Immunosuppressants in patients with neurological manifestations of rheumatological pathologies: An overview review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cajamarca-Barón]]></surname>
<given-names><![CDATA[Jairo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guavita-Navarro]]></surname>
<given-names><![CDATA[Diana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A4"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bedoya-Loaiza]]></surname>
<given-names><![CDATA[Esteban]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rojas-Villarraga]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Vallejos Narváez]]></surname>
<given-names><![CDATA[Álvaro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Navas Granados]]></surname>
<given-names><![CDATA[Angela Viviana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castañeda-Gonzalez]]></surname>
<given-names><![CDATA[Juan Pablo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Acelas-Gonzalez]]></surname>
<given-names><![CDATA[Gabriel E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital San José  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Fundación Universitaria de Ciencias de la Salud  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Gastro Reuma IPS  ]]></institution>
<addr-line><![CDATA[Yopal ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Fundación Universitaria de Ciencias de la Salud  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,Fundación Universitaria de Ciencias de la Salud  ]]></institution>
<addr-line><![CDATA[Bogotá ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2025</year>
</pub-date>
<volume>41</volume>
<numero>1</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0120-87482025000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0120-87482025000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0120-87482025000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Un diagnóstico rápido del compromiso neurológico en las enfermedades reumáticas es esencial para iniciar un tratamiento oportuno y prevenir la progresión de la enfermedad.  Objetivo: Describir las características principales de los inmunosupresores utilizados en las patologías reumáticas con afectación del sistema nervioso.  Materiales y métodos:  Se realizó una revisión panorámica mediante una búsqueda ampliada de la literatura en bases de datos como Pubmed, Cochrane y BVS, así como en literatura gris.  Resultados: Se identificaron los inmunosupresores más usados en patologías reumáticas con afectación neurológica. La ciclofosfamida, azatioprina, micofenolato y rituximab tienen indicaciones específicas. Es crucial monitorear su toxicidad, priorizando la función renal en inmunoglobulina y la hematológica en otros fármacos.  Discusión: La ciclofosfamida es un agente alquilante indicado en afecciones neurológicas causadas por patologías como lupus eritematoso sistémico (LES), síndrome de Sjögren, sarcoidosis, enfermedad de Behçet, entre otras, y forma parte de esquemas como el NIH y el CYCLOPS. La azatioprina, un análogo de las purinas, se utiliza en enfermedades como lupus neuropsiquiátrico y neuro-Behçet, entre otras, compartiendo indicaciones similares al micofenolato. El rituximab actúa contra el antígeno CD20 de las células B y se usa en diferentes dosis para múltiples compromisos neurorreumatológicos. Es fundamental realizar un monitoreo de estos medicamentos, especialmente de su toxicidad hematológica, con excepción de la inmunoglobulina, en cuyo caso se debe vigilar la función renal y el riesgo de episodios trombóticos.  Conclusiones: El conocimiento de las terapias utilizadas en las complicaciones neurológicas de patologías reumáticas, así como la monitorización y prevención de eventos adversos, es fundamental para optimizar el manejo del paciente.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: A prompt diagnosis of neurological involvement in rheumatic diseases is essential to initiate timely treatment and prevent disease progression.  Purpose: To describe the main characteristics of immunosuppressants used in rheumatic diseases with nervous system involvement.  Materials and Methods: A scoping review was conducted through an extensive literature search in databases such as PUBMED, Cochrane, and BVS, as well as in gray literature.  Results: The most commonly used immunosuppressants in rheumatic diseases with neurological involvement were identified. Cyclophosphamide, azathioprine, mycophenolate, and rituximab have specific indications. Monitoring their toxicity is crucial, prioritizing renal function for immunoglobulin and hematologic toxicity for other drugs.  Discussion: Cyclophosphamide is an alkylating agent indicated in neurological conditions caused by pathologies such as systemic lupus erythematosus (SLE), Sjögren's syndrome, sarcoidosis, Behçet, among others, and is part of schemes such as NIH and CYCLOPS. Azathioprine, a purine analogue, is used in diseases such as neuropsychiatric lupus and neuro-Behçet, among others, sharing similar indications to mycophenolate. Rituximab acts against the B-cell CD20 antigen and is used in different doses for multiple neuro-rheumatological conditions. Monitoring of these drugs, especially for haematological toxicity, is essential, with the exception of immunoglobulin, in which case renal function and the risk of thrombotic events should be monitored.  Conclusions: Knowledge of therapies used to treat neurological complications in rheumatic diseases, along with monitoring and preventing adverse events, is crucial to optimizing patient management.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[enfermedades autoinmunes]]></kwd>
<kwd lng="es"><![CDATA[manifestaciones neurológicas]]></kwd>
<kwd lng="es"><![CDATA[sistema nervioso central]]></kwd>
<kwd lng="es"><![CDATA[terapia de inmunosupresión]]></kwd>
<kwd lng="es"><![CDATA[farmacocinética]]></kwd>
<kwd lng="es"><![CDATA[toxicidad]]></kwd>
<kwd lng="en"><![CDATA[Autoimmune Diseases]]></kwd>
<kwd lng="en"><![CDATA[Central Nervous System]]></kwd>
<kwd lng="en"><![CDATA[Immunosuppression Therapy]]></kwd>
<kwd lng="en"><![CDATA[Neurologic Manifestations]]></kwd>
<kwd lng="en"><![CDATA[Pharmacokinetics]]></kwd>
<kwd lng="en"><![CDATA[Toxicity]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ahn]]></surname>
<given-names><![CDATA[GY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Won]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Song]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sohn]]></surname>
<given-names><![CDATA[IW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2018</year>
<volume>27</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>1338-47</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sloan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bourgeois]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Leschziner]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pollak]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Pitkanen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Harwood]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric prodromes and symptom timings in relation to disease onset and/or flares in SLE: results from the mixed methods international INSPIRE study]]></article-title>
<source><![CDATA[EClinicalMedicine]]></source>
<year>2024</year>
<numero>73</numero>
<issue>73</issue>
<page-range>102634</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Legge]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Hanly]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recent advances in the diagnosis and management of neuropsychiatric lupus]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2024</year>
<volume>20</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>712-28</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rice-Canetto]]></surname>
<given-names><![CDATA[TE]]></given-names>
</name>
<name>
<surname><![CDATA[Joshi]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kyan]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Siddiqi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric systemic lupus erythematosus: a systematic review]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2024</year>
<volume>16</volume>
<numero>6</numero>
<issue>6</issue>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Serdaroglu]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Behcet's disease and the nervous system]]></article-title>
<source><![CDATA[J Neurol]]></source>
<year>1998</year>
<volume>245</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>197-205</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stern]]></surname>
<given-names><![CDATA[BJ]]></given-names>
</name>
<name>
<surname><![CDATA[Krumholz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Johns]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Nissim]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sarcoidosis and its neurological manifestations]]></article-title>
<source><![CDATA[Arch Neurol]]></source>
<year>1985</year>
<volume>42</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>909-17</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smiyan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Komorovsky]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Koshak]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Duve]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shkrobot]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Central nervous system manifestations in rheumatic diseases]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2024</year>
<volume>44</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>1803-12</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jazayeri]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Rahimian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ahadi]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Tavakolpour]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Alesaeidi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurologic involvement in granulomatosis with poly-angiitis: a comparative study]]></article-title>
<source><![CDATA[Biol Life Sci Forum]]></source>
<year>2022</year>
<volume>19</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>19</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[DeQuattro]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Imboden]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurologic manifestations of rheumatoid arthritis]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2017</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>561-71</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galiano]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[CICLOFOSFAMIDA]]></article-title>
<source><![CDATA[Vademecum]]></source>
<year>2009</year>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Cos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Merino]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología de la respuesta inmunitaria]]></article-title>
<source><![CDATA[Farmacología humana]]></source>
<year>2014</year>
<page-range>305-89</page-range><publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iglesias-Gamarra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Peñaranda-Parada]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cajas-Santana]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Quintana-López]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Restrepo-Suárez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Arbeláez-Cortés]]></surname>
<given-names><![CDATA[Á]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Historia del tratamiento de las vasculitis primarias]]></article-title>
<source><![CDATA[Rev Colomb Reumatol]]></source>
<year>2012</year>
<volume>19</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>131-57</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagley]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Bostick]]></surname>
<given-names><![CDATA[FW]]></given-names>
</name>
<name>
<surname><![CDATA[DeVita]]></surname>
<given-names><![CDATA[VT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacology of cyclophosphamide]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1973</year>
<volume>33</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>226-33</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wiernik]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Duncan]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide in human milk]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1971</year>
<volume>1</volume>
<numero>7705</numero>
<issue>7705</issue>
<page-range>912</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haubitz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bohnenstengel]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Brunkhorst]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Schwab]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hofmann]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Busse]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency]]></article-title>
<source><![CDATA[Kidney Int]]></source>
<year>2002</year>
<volume>61</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1495-501</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Jao]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Enzymatic basis of cyclophosphamide activation by hepatic microsomes of the rat]]></article-title>
<source><![CDATA[J Pharmacol Exp Ther]]></source>
<year>1970</year>
<volume>174</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>206-10</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Struck]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
<name>
<surname><![CDATA[Alberts]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Horne]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Phillips]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Roe]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma pharmacokinetics of cyclophosphamide and its cytotoxic metabolites after intravenous versus oral administration in a randomized, crossover trial]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1987</year>
<volume>47</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>2723-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Regan]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hellmann]]></surname>
<given-names><![CDATA[DB]]></given-names>
</name>
<name>
<surname><![CDATA[Stone]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatement of Wegener's granulomatosis]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2001</year>
<volume>27</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>863-86</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colvin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brundrett]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Kan]]></surname>
<given-names><![CDATA[MN]]></given-names>
</name>
<name>
<surname><![CDATA[Jardine]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Fenselau]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alkylating properties of phosphoramide mustard]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>1976</year>
<volume>36</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>1121-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hall]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Tilby]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies]]></article-title>
<source><![CDATA[Blood Rev]]></source>
<year>1992</year>
<volume>6</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>163-73</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Winkelstein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanisms of immunosuppression: effects of cyclophosphamide on cellular immunity]]></article-title>
<source><![CDATA[Blood]]></source>
<year>1973</year>
<volume>41</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>273-84</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brode]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Raine]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zaccone]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cooke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide-induced type-1 diabetes in the NOD mouse is associated with a reduction of CD4+CD25+Foxp3+ Regulatory T Cells]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2006</year>
<volume>177</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>6603-12</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gourley]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Austin]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yarboro]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Vaughan]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Muir]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>1996</year>
<volume>125</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>549-57</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Houssiau]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Vasconcelos]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[D'Cruz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sebastiani]]></surname>
<given-names><![CDATA[GD]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Danieli]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2002</year>
<volume>46</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2121-31</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papp]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Haraoui]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Marshall]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Bissonnette]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bitton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies]]></article-title>
<source><![CDATA[J Cutan Med Surg]]></source>
<year>2019</year>
<volume>23</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-74</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Donelli]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Bartosek]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Guaitani]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Martini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Colombo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pacciarini]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Importance of pharmacokinetic studies on cyclophosphamide (NSC-26271) in understanding its cytotoxic effect]]></article-title>
<source><![CDATA[Cancer Treat Rep]]></source>
<year>1976</year>
<volume>60</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>395-401</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Koyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nishizawa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Iwanaga]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Aoki]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide-induced ovarian failure and its therapeutic significance in patients with breast cancer]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1977</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1403-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stahl]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stember]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Hsiao]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Schlegel]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indications and strategies for fertility preservation in men]]></article-title>
<source><![CDATA[Clin Obstet Gynecol]]></source>
<year>2010</year>
<volume>53</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>815-27</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zard]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Arnaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mathian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chakhtoura]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Hie]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Touraine]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased risk of high grade cervical squamous intraepithelial lesions in systemic lupus erythematosus: a meta-analysis of the literature]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2014</year>
<volume>13</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>730-5</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yilmaz]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Kertmen]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Gürer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kanat]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Arikok]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Ergüder]]></surname>
<given-names><![CDATA[BI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The protective effect of 2-mercaptoethane sulfonate (MESNA) against traumatic brain injury in rats]]></article-title>
<source><![CDATA[Acta Neurochir]]></source>
<year>2013</year>
<volume>155</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>141-9</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCune]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Golbus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Zeldes]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Bohlke]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Dunne]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and immunologic effects of monthly administration of intravenous cyclophosphamide in severe systemic lupus erythematosus]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1988</year>
<volume>318</volume>
<numero>22</numero>
<issue>22</issue>
<page-range>1423-31</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Galindo-Rodriguez]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Aviña-Zubieta]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pizarro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Diaz de León]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Saucedo]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cyclophosphamide pulse therapy in optic neuritis due to systemic lupus erythematosus: an open trial]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1999</year>
<volume>106</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-9</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Taboada]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Blanco Alonso]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Armona]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Femandez-Sueiro]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzalez Vela]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguez-Valverde]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>1996</year>
<volume>5</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>74-6</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bertsias]]></surname>
<given-names><![CDATA[GK]]></given-names>
</name>
<name>
<surname><![CDATA[Ioannidis]]></surname>
<given-names><![CDATA[JPA]]></given-names>
</name>
<name>
<surname><![CDATA[Aringer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bollen]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bombardieri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Bruce]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2010</year>
<volume>69</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>2074-82</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carsons]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
<name>
<surname><![CDATA[Vivino]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Parke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Carteron]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sankar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Brasington]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment guidelines for rheumatologic manifestations of Sjogren's syndrome: use of biologic agents, management of fatigue, and inflammatory musculoskeletal pain]]></article-title>
<source><![CDATA[Arthritis Care Res]]></source>
<year>2017</year>
<volume>69</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>517-27</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guillevin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pagnoux]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[When should immunosuppressants be prescribed to treat systemic vasculitides?]]></article-title>
<source><![CDATA[Intern Med]]></source>
<year>2003</year>
<volume>42</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>313-7</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gayraud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Guillevin]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lhote]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cacoub]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Deblois]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of good-prognosis polyarteritis nodosa and Churg-Strauss syndrome: comparison of steroids and oral or pulse cyclophosphamide in 25 patients. French Cooperative Study Group for Vasculitides]]></article-title>
<source><![CDATA[Br J Rheumatol]]></source>
<year>1997</year>
<volume>36</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>1290-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scott]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Bacon]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous cyclophosphamide plus methylprednisolone in treatment of systemic rheumatoid vasculitis]]></article-title>
<source><![CDATA[Am J Med]]></source>
<year>1984</year>
<volume>76</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>377-84</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniel]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
<name>
<surname><![CDATA[Dickson]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[CP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Precision medicine for rheumatologists: lessons from the pharmacogenomics of azathioprine]]></article-title>
<source><![CDATA[Clin Rheumatol]]></source>
<year>2021</year>
<volume>40</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>65-73</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Broen]]></surname>
<given-names><![CDATA[JCA]]></given-names>
</name>
<name>
<surname><![CDATA[van Laar]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2020</year>
<volume>16</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>167-78</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mohammadi]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Kassim]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Azathioprine]]></article-title>
<source><![CDATA[StatPearls]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Florida ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misdaq]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ziegler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[von Ahsen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Oellerich]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Asif]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thiopurines induce oxidative stress in T-lymphocytes: a pro-teomic approach]]></article-title>
<source><![CDATA[Mediators Inflamm]]></source>
<year>2015</year>
<page-range>434825</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Coulthard]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hogarth]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The thiopurines: an update]]></article-title>
<source><![CDATA[Invest New Drugs]]></source>
<year>2005</year>
<volume>23</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>523-32</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sahasranaman]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Roy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacology and pharmacogenetics of thiopurines]]></article-title>
<source><![CDATA[Eur J Clin Pharmacol]]></source>
<year>2008</year>
<volume>64</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>753-67</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Boer]]></surname>
<given-names><![CDATA[NKH]]></given-names>
</name>
<name>
<surname><![CDATA[van Bodegraven]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Jharap]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[de Graaf]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mulder]]></surname>
<given-names><![CDATA[CJJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Drug insight: pharmacology and toxicity of thiopu-rine therapy in patients with IBD]]></article-title>
<source><![CDATA[Nat Clin Pract Gastroenterol Hepatol]]></source>
<year>2007</year>
<volume>4</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>686-94</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moon]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Loftus]]></surname>
<given-names><![CDATA[EV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2016</year>
<volume>43</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>863-83</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roblin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Williet]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Peyrin-Biroulet]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thiopurine metabolism in the era of combotherapy]]></article-title>
<source><![CDATA[Inflamm Bowel Dis]]></source>
<year>2016</year>
<volume>22</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1496-501</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katara]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kuntal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TPMT polymorphism: when shield becomes weakness]]></article-title>
<source><![CDATA[Interdiscip Sci]]></source>
<year>2016</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>150-5</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Espiritu]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[D Pasco]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy and tolerability of azathioprine for neuromyelitis optica spectrum disorder: a systematic review and meta-analysis]]></article-title>
<source><![CDATA[Mult Scler Relat Disord]]></source>
<year>2019</year>
<numero>33</numero>
<issue>33</issue>
<page-range>22-32</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wingerchuk]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Lucchinetti]]></surname>
<given-names><![CDATA[CF.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuromyelitis optica spectrum disorder]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2022</year>
<volume>387</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>631-9</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrión-Barberà]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Salman-Monte]]></surname>
<given-names><![CDATA[TC]]></given-names>
</name>
<name>
<surname><![CDATA[Vílchez-Oya]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Monfort]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric involvement in systemic lupus erythematosus: a review]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2021</year>
<volume>20</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>102780</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McWilliam]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Azathioprine and the neurologist]]></article-title>
<source><![CDATA[Pract Neurol]]></source>
<year>2020</year>
<volume>20</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>69-74</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hatemi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bodaghi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Celik]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Fortune]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2018 update of the EULAR recommendations for the management of Behcet's syndrome]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2018</year>
<volume>77</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>808-18</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Watelet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Samson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[de Boysson]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Bienvenu]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of giant-cell arteritis, a literature review]]></article-title>
<source><![CDATA[Mod Rheumatol]]></source>
<year>2017</year>
<volume>27</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>747-54</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pugh]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Karabayas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Basu]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Cid]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Goel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Goodyear]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Large-vessel vasculitis]]></article-title>
<source><![CDATA[Nat Rev Dis Primers]]></source>
<year>2022</year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>93</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sarwar]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Rogers]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sarmast]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
<name>
<surname><![CDATA[Kataria]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mohamed]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neuropsychiatric systemic lupus erythematosus: a 2021 update on diagnosis, management, and current challenges]]></article-title>
<source><![CDATA[Cureus]]></source>
<year>2021</year>
<volume>13</volume>
<numero>9</numero>
<issue>9</issue>
</nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moretti]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Focus on neuro-Behçet's disease: a review]]></article-title>
<source><![CDATA[Neurol India]]></source>
<year>2018</year>
<volume>66</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1619-28</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhat]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tonutti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Timilsina]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Selmi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gershwin]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Perspectives on mycophenolate mofetil in the management of autoimmunity]]></article-title>
<source><![CDATA[Clin Rev Allergy Immunol]]></source>
<year>2023</year>
<volume>65</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>86-100</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van Gelder]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hesselink]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mycophenolate revisited]]></article-title>
<source><![CDATA[Transpl Int]]></source>
<year>2015</year>
<volume>28</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>508-15</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beuker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Strunk]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Sporns]]></surname>
<given-names><![CDATA[PB]]></given-names>
</name>
<name>
<surname><![CDATA[Wiendl]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Meuth]]></surname>
<given-names><![CDATA[SG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary angiitis of the central nervous system: diagnosis and treatment]]></article-title>
<source><![CDATA[Ther Adv Neurol Disord]]></source>
<year>2018</year>
<numero>11</numero>
<issue>11</issue>
<page-range>1756286418785071</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mandal]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Primary angiitis of the central nervous system]]></article-title>
<source><![CDATA[Rheum Dis Clin North Am]]></source>
<year>2017</year>
<volume>43</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>503-18</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schneider-Gold]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hartung]]></surname>
<given-names><![CDATA[HP]]></given-names>
</name>
<name>
<surname><![CDATA[Gold]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mycophenolate mofetil and tacrolimus: new therapeutic options in neuroim-munological diseases]]></article-title>
<source><![CDATA[Muscle Nerve]]></source>
<year>2006</year>
<volume>34</volume>
<page-range>284-91</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Current classification and management of inflammatory myopathies]]></article-title>
<source><![CDATA[J Neuromuscul Dis]]></source>
<year>2018</year>
<volume>5</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>109-29</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pregnancy-induced leukocytosis: a case report]]></article-title>
<source><![CDATA[World J Clin Cases]]></source>
<year>2022</year>
<volume>10</volume>
<numero>36</numero>
<issue>36</issue>
<page-range>13349-55</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hauser]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Malek]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Rosen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil]]></article-title>
<source><![CDATA[Neurology]]></source>
<year>1998</year>
<volume>51</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>912-3</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Omair]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Alahmadi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Safety and effectiveness of mycophenolate in systemic sclerosis. A systematic review]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2015</year>
<volume>10</volume>
<numero>5</numero>
<issue>5</issue>
</nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Leandro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Isenberg]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab - The first twenty years]]></article-title>
<source><![CDATA[Lupus]]></source>
<year>2021</year>
<volume>30</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>371-7</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maloney]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Grillo-Lopez]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[White]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Bodkin]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Schilder]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neidhart]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IDEC-C2B8 (Rituximab) anti-cd20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma]]></article-title>
<source><![CDATA[Blood]]></source>
<year>1997</year>
<volume>90</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>2188-95</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="book">
<collab>Drugbank</collab>
<source><![CDATA[Rituximab]]></source>
<year>2011</year>
<publisher-loc><![CDATA[Canadá ]]></publisher-loc>
<publisher-name><![CDATA[Drugbank]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bohelay]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Caux]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Musette]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and biological activity of rituximab in the treatment of pemphigus]]></article-title>
<source><![CDATA[Immunotherapy]]></source>
<year>2021</year>
<volume>13</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>35-53</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sood]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hariharan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-CD20 blocker rituximab in kidney transplantation]]></article-title>
<source><![CDATA[Transplantation]]></source>
<year>2018</year>
<volume>102</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>44-58</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Blosser]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jupp]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Yau]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical pharmacokinetic and pharmacodynamic considerations in treating non-Hodgkin lymphoma]]></article-title>
<source><![CDATA[Clin Pharmacokinet]]></source>
<year>2020</year>
<volume>59</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>7-23</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="">
<collab>Grupo de Trabajo sobre Terapias Biológicas en EAS, Grupo de Estudio de Enfermedades Autoinmunes, Sociedad Española de Medicina Interna</collab>
<source><![CDATA[Guías Práctica Clínica. Recomendaciones sobre el uso off-label de rituximab en enfermedades autoinmunes sistémicas]]></source>
<year>2009</year>
<publisher-loc><![CDATA[España ]]></publisher-loc>
</nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lünemann]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Nimmerjahn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Dalakas]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulin in neurology-mode of action and clinical efficacy]]></article-title>
<source><![CDATA[Nat Rev Neurol]]></source>
<year>2015</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>80-9</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Gelinas]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Freimer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Runken]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Wolfe]]></surname>
<given-names><![CDATA[GI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunoglobulin administration for the treatment of CIDP: IVIG or SCIG?]]></article-title>
<source><![CDATA[J Neurol Sci]]></source>
<year>2020</year>
<numero>408</numero>
<issue>408</issue>
<page-range>116497</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prins]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gelfand]]></surname>
<given-names><![CDATA[EW]]></given-names>
</name>
<name>
<surname><![CDATA[French]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous immunoglobulin: properties, mode of action and practical use in dermatology]]></article-title>
<source><![CDATA[Acta Derm Venereol]]></source>
<year>2007</year>
<volume>87</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>206-18</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stiehm]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adverse effects of human immunoglobulin therapy]]></article-title>
<source><![CDATA[Transfus Med Rev]]></source>
<year>2013</year>
<volume>27</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>171-8</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vodopivec]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Miloslavsky]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Kotton]]></surname>
<given-names><![CDATA[CN]]></given-names>
</name>
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A neurologist's guide to safe use of immunomodulatory therapies]]></article-title>
<source><![CDATA[Semin Neurol]]></source>
<year>2014</year>
<volume>34</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>467-78</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Morales-Ruiz]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Juárez-Vaquera]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
<name>
<surname><![CDATA[Rosetti-Sciutto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Muñoz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Adalid-Peralta]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2022</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>103019</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yeh]]></surname>
<given-names><![CDATA[WZ]]></given-names>
</name>
<name>
<surname><![CDATA[Dyck]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[van den Berg]]></surname>
<given-names><![CDATA[LH]]></given-names>
</name>
<name>
<surname><![CDATA[Kiernan]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor]]></surname>
<given-names><![CDATA[BV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Multifocal motor neuropathy: controversies and priorities]]></article-title>
<source><![CDATA[J Neurol Neurosurg Psychiatry]]></source>
<year>2020</year>
<numero>91</numero>
<issue>91</issue>
<page-range>140-8</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eftimov]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lucke]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
<name>
<surname><![CDATA[Querol]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Rajabally]]></surname>
<given-names><![CDATA[YA]]></given-names>
</name>
<name>
<surname><![CDATA[Verhamme]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnostic challenges in chronic inflammatory demyelinating polyradiculoneuropathy]]></article-title>
<source><![CDATA[Brain]]></source>
<year>2020</year>
<volume>143</volume>
<numero>11</numero>
<issue>11</issue>
<page-range>3214-24</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mulhearn]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Bruce]]></surname>
<given-names><![CDATA[IN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indications for IVIG in rheumatic diseases]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2015</year>
<volume>54</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>383-91</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arumugham]]></surname>
<given-names><![CDATA[VB]]></given-names>
</name>
<name>
<surname><![CDATA[Rayi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Intravenous Immunoglobulin (IVIG)]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Florida ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brummaier]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Pohanka]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Studnicka-Benke]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pieringer]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Using cyclophosphamide in inflammatory rheumatic diseases]]></article-title>
<source><![CDATA[Eur J Intern Med]]></source>
<year>2013</year>
<volume>24</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>590-6</page-range></nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanif]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Anwer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Rituximab]]></article-title>
<source><![CDATA[StatPearls]]></source>
<year>2023</year>
<publisher-loc><![CDATA[Florida ]]></publisher-loc>
<publisher-name><![CDATA[StatPearls Publishing]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fragoulis]]></surname>
<given-names><![CDATA[GE]]></given-names>
</name>
<name>
<surname><![CDATA[Nikiphorou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dey]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Courvoisier]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Arnaud]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2023</year>
<volume>82</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>742-53</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Chakravarty]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Akl]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Bingham]]></surname>
<given-names><![CDATA[CO]]></given-names>
</name>
<name>
<surname><![CDATA[Calabrese]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cappelli]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2023</year>
<volume>75</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>333-48</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ballow]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tratamiento con inmunoglobulinas: reposición e inmunomodulación]]></article-title>
<source><![CDATA[Inmunología clínica: principios y práctica]]></source>
<year>2020</year>
<page-range>1143-53</page-range><publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schutgens]]></surname>
<given-names><![CDATA[REG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First-line therapy for immune thrombocytopenia: time for change]]></article-title>
<source><![CDATA[Hemasphere]]></source>
<year>2022</year>
<volume>6</volume>
<numero>10</numero>
<issue>10</issue>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
